Noile-Immune BiotechTSE:4893 53 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, Noile-Immune Biotech ranks worse than 136425.51% on this metric.
The historical rank and industry rank for Noile-Immune Biotech's Gross Margin % or its related term are showing as below:
During the past 6 years, the highestGross Margin % of Noile-Immune Biotech was 99.29%. The lowest was 77.27%. And the median was 97.43%.
TSE:4893's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9 * Ranked among companies with meaningful Gross Margin % only.
Noile-Immune Biotech had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Noile-Immune Biotech was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Noile-Immune Biotech had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Noile-Immune Biotech Gross Margin % Related Terms
Noile-Immune Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Noile-Immune Biotech (TSE:4893) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Noile-Immune Biotech and its competitors. Over the past decade, Noile-Immune Biotech's Gross Margin % has ranged from 77.27 to 99.29. According to the industry distribution chart, Noile-Immune Biotech ranks #999999 out of 733 companies in the Biotechnology industry.
Is Noile-Immune Biotech's Gross Margin % too high?
Noile-Immune Biotech's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 77.27 to a high of 99.29. Based on the distribution chart, Noile-Immune Biotech ranks #999999 out of 733 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #999999 out of 733 companies for Gross Margin %. This places Noile-Immune Biotech in the lower half of its industry. The industry median Gross Margin % is 60.90. Historically, Noile-Immune Biotech's own Gross Margin % has ranged from 77.27 to 99.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円123.00 — trading 2721.1% above its estimated fair value. The current Gross Margin % is 0.00%. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円123.00 is trading 2721.1% above its estimated GF Value™ of 円4.36.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Gross Margin %: 0.00%
GF Value™: 円4.36 vs. price of 円123.00 (2721.1% above fair value)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
